Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
TNC
REST API REST API
Homo sapiens
TNC is differentially expressed in 299 experiments: 179 organism parts: liver, prostate, ... (177 more);, 217 disease states: normal, glioblastoma, ... (215 more);, 95 cell types 468 cell lines 34 compound treatments and 76 other conditions.
Synonyms TN, HXB, MGC167029
Orthologs TNC (Gallus gallus)   Tnc (Mus musculus)   TNC (2 of 2) (Danio rerio)   tnc (Danio rerio)   ENSCING00000003482 (Ciona intestinalis)   TNC (Bos taurus)   tnc (Xenopus laevis)   TNC (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, response to wounding, neuromuscular junction development, extracellular space, positive regulation of cell proliferation, positive regulation of gene expression, extracellular region, receptor binding, basement membrane, cell adhesion, binding, extracellular matrix, signal transduction, syndecan binding, interstitial matrix, prostate gland epithelium morphogenesis, mesenchymal-epithelial cell signaling involved in prostate gland development, peripheral nervous system axon regeneration
InterPro Term Fibrinogen_a/b/g_C, EGF_extracell, EGF_3, EGF-like, Fibronectin_type3
UniProt Accession P24821, A9YUB8, F5H7V9, E7EVS8, E9PC84, F5H5D6
Search EB-eye ENSG00000041982
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-GEOD-3526, ... (30 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, ... (41 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-5823, E-GEOD-19639, E-GEOD-3529
LNCaP
2
E-GEOD-14464, E-GEOD-14990
BT-474
2
E-GEOD-5823, E-GEOD-3529
HCC38
2
E-MTAB-37, E-MTAB-62
MDA468
2
E-MEXP-440, E-MTAB-62
MDAMB453
2
E-MTAB-37, E-MTAB-62
462 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-21668, E-GEOD-3920, E-MEXP-66, E-GEOD-20677, ... (42 experiments)

Factor Value U/D Experiments
whole blood
2
E-MTAB-25, E-GEOD-3026
CD4+ T cell
2
E-AFMX-5, E-MTAB-24
CD8+ T cell
2
E-AFMX-5, E-MTAB-25
human foreskin fibroblast
1
E-GEOD-18265
mature monocyte derived dendritic cell
1
E-GEOD-4984
neuroblastoma cell
1
E-MEXP-669
89 more value(s).


Disease state

studied in E-GEOD-3307, E-MEXP-1121, E-GEOD-1577, E-MEXP-2280, E-MTAB-62, ... (67 experiments)

Factor Value U/D Experiments
glioblastoma
5
E-GEOD-6014, E-MTAB-37, E-MTAB-62, E-GEOD-4290, E-MEXP-567 ... (5 experiments)
prostate carcinoma
3
E-MEXP-2034, E-MTAB-62, E-TABM-26
AIDS-KS, HIV+, nodular (late) stage
1
2
E-MEXP-66, E-MTAB-62
astrocytoma
2
E-GEOD-4290, E-MTAB-62
cervical carcinoma
2
E-MTAB-62, E-MEXP-1331
obesity
2
E-MTAB-62, E-GEOD-2508
211 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-15205, E-GEOD-3720, E-GEOD-5824, E-GEOD-4748, ... (22 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-GEOD-4748, E-TABM-868
baseline propofol
1
E-GEOD-4386
ponasterone A
1
E-GEOD-3113
1,25-dihydroxyvitamin D3
2
1
E-GEOD-995
5-aza-2'-deoxycytidine + trichostatin A
2
1
E-GEOD-5230
AMP
1
E-MEXP-2285
28 more value(s).


Age years

studied in E-TABM-783

Factor Value U/D Experiments
n/a
1
1
E-TABM-783
1
1
E-TABM-783


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-2191, E-GEOD-19246, ... (10 experiments)

Clinical treatment
studied in E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-20033, E-MEXP-2359, E-GEOD-3891, E-MEXP-958, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-GEOD-2509, ... (8 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-GEOD-6431, E-GEOD-361, ... (7 experiments)

Genotype
studied in E-GEOD-17476, E-GEOD-22593, E-GEOD-2292, E-TABM-868, E-GEOD-18005, ... (9 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-20540, E-GEOD-10315, E-TABM-440, E-GEOD-1692, E-MEXP-1273, ... (15 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-GEOD-1926, E-TABM-118, E-GEOD-16363, E-GEOD-430, ... (33 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-9723, E-GEOD-980, ... (7 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-461, E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-1309, E-GEOD-21750, E-GEOD-1657, E-GEOD-17636, ... (6 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-3254, E-GEOD-19246, E-GEOD-1343, E-GEOD-20037

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-1676, E-MEXP-101, E-GEOD-3697, E-MEXP-2759

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19069, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-23984

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-3494, E-TABM-147

Processing time: 0.469 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM